ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 231,22
0,53%
Dow Jones
39 563,53
0,45%
DAX
18 777,55
0,52%
Brent Oil
84,065
0,14%
Bitcoin
62 951,57
-0,15%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Precision BioSciences Inc (DTIL)

  7. Precision BioSciences Inc (DTIL) Actualités

DTIL

Precision BioSciences (DTIL)

Precision BioSciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DTIL
DateHeureSourceTitreSymboleSociété
09/05/202402h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
08/05/202414h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
08/05/202414h15Business WirePrecision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private PlacementNASDAQ:DTILPrecision BioSciences Inc
07/05/202422h30Business WirePrecision BioSciences to Report First Quarter Results on May 13, 2024NASDAQ:DTILPrecision BioSciences Inc
07/05/202414h30Business WirePrecision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
01/05/202413h05Business WirePrecision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024NASDAQ:DTILPrecision BioSciences Inc
16/04/202422h15Business WirePrecision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail TherapeuticsNASDAQ:DTILPrecision BioSciences Inc
27/03/202411h45Business WirePrecision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
20/03/202421h30Business WirePrecision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024NASDAQ:DTILPrecision BioSciences Inc
19/03/202412h00Business WirePrecision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial MyopathyNASDAQ:DTILPrecision BioSciences Inc
06/03/202414h45Business WirePrecision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC DeficiencyNASDAQ:DTILPrecision BioSciences Inc
01/03/202412h30Business WirePrecision BioSciences Announces $40.0 Million Offering of Common Stock and WarrantsNASDAQ:DTILPrecision BioSciences Inc
01/03/202412h00Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:DTILPrecision BioSciences Inc
29/02/202423h19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DTILPrecision BioSciences Inc
29/02/202422h01Business WirePrecision BioSciences Announces Proposed Public Offering of Common Stock and WarrantsNASDAQ:DTILPrecision BioSciences Inc
20/02/202413h00Business WirePrecision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou BiosciencesNASDAQ:DTILPrecision BioSciences Inc
14/02/202413h00Business WirePrecision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical ReadinessNASDAQ:DTILPrecision BioSciences Inc
13/02/202413h00Business WirePrecision BioSciences Promotes Naresh Tanna to Vice President of Investor RelationsNASDAQ:DTILPrecision BioSciences Inc
12/02/202417h00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DTILPrecision BioSciences Inc
12/02/202413h00Business WirePrecision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune DiseasesNASDAQ:DTILPrecision BioSciences Inc
09/02/202413h00Business WirePrecision BioSciences to Effect a Reverse Stock SplitNASDAQ:DTILPrecision BioSciences Inc
23/01/202422h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
12/01/202414h00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DTILPrecision BioSciences Inc
09/01/202415h20AllPennyStocks.comBiotech Massively Bid Up Before Opening BellNASDAQ:DTILPrecision BioSciences Inc
09/01/202413h00GlobeNewswire Inc.TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune DiseasesNASDAQ:DTILPrecision BioSciences Inc
09/01/202413h00Business WirePrecision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune DiseasesNASDAQ:DTILPrecision BioSciences Inc
13/12/202314h20Business WirePrecision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURENASDAQ:DTILPrecision BioSciences Inc
04/12/202322h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:DTILPrecision BioSciences Inc
04/12/202313h00Business WirePrecision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial DiseasesNASDAQ:DTILPrecision BioSciences Inc
30/11/202313h00Business WirePrecision BioSciences to Present at Hep-DART 2023NASDAQ:DTILPrecision BioSciences Inc
 Showing the most relevant articles for your search:NASDAQ:DTIL

Dernières Valeurs Consultées

EU
ACA
Credit Agricole
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
EU
CAP
Capgemini
EU
SGO
Cie de SaintGobain
EU
VIV
Vivendi
NYSE
JPM
JP Morgan Chase
USI
USTECH100
US Tech 100
EU
HO
Thales
EU
BNP
BNP Paribas
EU
AI
Air Liquide
COIN
ETHUSD
Ethereum
EU
CS
Axa
EU
PX4
SBF 120
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés